REMEGEN CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.95 HKD | +5.10% |
|
+14.31% | -14.69% |
| Apr. 26 | RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 04 | Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 39,166 | 31,092 | 36,877 | 28,299 | 25,715 | - | - |
| Enterprise Value (EV) 1 | 36,595 | 29,387 | 34,808 | 28,741 | 26,583 | 27,370 | 28,266 |
| P/E ratio | -56.1 x | 111 x | -27.2 x | -11.9 x | -14.1 x | -23.5 x | -77.5 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 21.8 x | 48 x | 26.1 x | 15 x | 9.87 x | 7.7 x |
| EV / Revenue | - | 20.6 x | 45.3 x | 26.5 x | 15.5 x | 10.5 x | 8.46 x |
| EV / EBITDA | -60.4 x | 80.3 x | -43.8 x | -21.7 x | -29.3 x | -66.1 x | 209 x |
| EV / FCF | -33.2 x | -83.6 x | -17.2 x | -12.2 x | -19.9 x | -39.6 x | -195 x |
| FCF Yield | -3.02% | -1.2% | -5.8% | -8.2% | -5.02% | -2.53% | -0.51% |
| Price to Book | 10.9 x | 8.98 x | 3.64 x | 5.34 x | 5.59 x | 6.64 x | 8.3 x |
| Nbr of stocks (in thousands) | 489,837 | 489,837 | 539,197 | 538,532 | 537,914 | - | - |
| Reference price 2 | 79.96 | 63.47 | 51.14 | 34.04 | 29.54 | 29.54 | 29.54 |
| Announcement Date | 3/26/21 | 2/20/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 1,426 | 767.8 | 1,083 | 1,718 | 2,605 | 3,340 |
| EBITDA 1 | - | -605.6 | 365.8 | -794.1 | -1,322 | -908.8 | -414 | 135.4 |
| EBIT 1 | - | -668.6 | 281.6 | -980.9 | -1,502 | -938.1 | -250.3 | 99 |
| Operating Margin | - | - | 19.74% | -127.76% | -138.65% | -54.61% | -9.61% | 2.96% |
| Earnings before Tax (EBT) 1 | - | -697.8 | 276.3 | -998.8 | -1,511 | -1,142 | -687.3 | -221.1 |
| Net income 1 | -430.3 | -697.8 | 276.3 | -998.8 | -1,511 | -1,138 | -688.9 | -216.7 |
| Net margin | - | - | 19.37% | -130.09% | -139.55% | -66.22% | -26.45% | -6.49% |
| EPS 2 | - | -1.425 | 0.5700 | -1.880 | -2.860 | -2.096 | -1.258 | -0.3809 |
| Free Cash Flow 1 | - | -1,104 | -351.4 | -2,019 | -2,356 | -1,335 | -692 | -144.8 |
| FCF margin | - | - | -24.64% | -263% | -217.51% | -77.71% | -26.57% | -4.33% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 10/28/20 | 3/26/21 | 2/20/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 S2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 |
|---|---|---|---|---|---|---|---|
| Net sales | - | 1,397 | - | - | 198.1 | 419 | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | 720.3 | - | - | - | -509.7 | - |
| Net income 1 | -444 | - | -489.1 | -199.1 | - | -509.7 | -323.8 |
| Net margin | - | - | - | - | - | -121.65% | - |
| EPS 2 | -0.9100 | - | -0.9600 | -0.3600 | - | - | -0.6000 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 8/23/21 | 2/20/22 | 8/30/22 | 10/27/22 | 2/27/23 | 2/27/23 | 4/27/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 442 | 869 | 1,655 | 2,551 |
| Net Cash position 1 | - | 2,571 | 1,704 | 2,069 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.3342 x | -0.9558 x | -3.996 x | 18.85 x |
| Free Cash Flow 1 | - | -1,104 | -351 | -2,019 | -2,356 | -1,335 | -692 | -145 |
| ROE (net income / shareholders' equity) | - | -41.5% | 7.85% | -23.7% | -35.5% | -38.6% | -34.8% | -21.6% |
| ROA (Net income/ Total Assets) | - | -29% | 6.68% | -19.6% | -26.2% | -19.9% | -11.9% | -6.48% |
| Assets 1 | - | 2,403 | 4,138 | 5,090 | 5,775 | 5,719 | 5,803 | 3,342 |
| Book Value Per Share 2 | - | 7.340 | 7.070 | 14.00 | 6.380 | 5.290 | 4.450 | 3.560 |
| Cash Flow per Share 2 | - | -1.620 | 0.5400 | -2.380 | - | -1.740 | -0.5100 | -0.1000 |
| Capex 1 | - | 443 | 615 | 756 | 853 | 449 | 322 | 245 |
| Capex / Sales | - | - | 43.12% | 98.41% | 78.74% | 26.13% | 12.35% | 7.32% |
| Announcement Date | 10/28/20 | 3/26/21 | 2/20/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
29.48
CNY
Average target price
38.75
CNY
Spread / Average Target
+31.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.69% | 3.48B | |
| +4.14% | 106B | |
| +7.02% | 23.47B | |
| -14.75% | 21.9B | |
| -7.05% | 18.77B | |
| -38.55% | 17.85B | |
| -9.80% | 16.78B | |
| +5.63% | 14.41B | |
| +34.72% | 12.86B | |
| +325.52% | 8.78B |
- Stock Market
- Equities
- 9995 Stock
- Financials RemeGen Co., Ltd.